Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

DUSP2 methylation is a candidate biomarker of outcome in head and neck cancer.

Lo Nigro C, Vivenza D, Denaro N, Lattanzio L, Fortunato M, Crook T, Merlano MC.

Ann Transl Med. 2018 Jul;6(13):271. doi: 10.21037/atm.2018.06.39.

2.

Head and neck cancer: improving outcomes with a multidisciplinary approach.

Lo Nigro C, Denaro N, Merlotti A, Merlano M.

Cancer Manag Res. 2017 Aug 18;9:363-371. doi: 10.2147/CMAR.S115761. eCollection 2017. Review.

3.

Prognostic Value of Different Allelic Polymorphism of Aldosterone Synthase Receptor in a Congestive Heart Failure European Continental Ancestry Population.

Feola M, Monteverde M, Vivenza D, Testa M, Leto L, Astesana V, Mussapi F, Vado A, Merlano M, Lo Nigro C.

Arch Med Res. 2017 Feb;48(2):156-161. doi: 10.1016/j.arcmed.2017.03.008.

PMID:
28625318
4.

Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy.

Lattanzio L, Denaro N, Vivenza D, Varamo C, Strola G, Fortunato M, Chamorey E, Comino A, Monteverde M, Lo Nigro C, Milano G, Merlano M.

Cancer Immunol Immunother. 2017 May;66(5):573-579. doi: 10.1007/s00262-017-1960-8. Epub 2017 Feb 14.

PMID:
28197666
5.

Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.

Guyot M, Hilmi C, Ambrosetti D, Merlano M, Lo Nigro C, Durivault J, Grépin R, Pagès G.

Oncotarget. 2017 Feb 7;8(6):9174-9188. doi: 10.18632/oncotarget.13942.

6.

MicroRNAs role as potential biomarkers and key regulators in melanoma.

Varamo C, Occelli M, Vivenza D, Merlano M, Lo Nigro C.

Genes Chromosomes Cancer. 2017 Jan;56(1):3-10. doi: 10.1002/gcc.22402. Epub 2016 Oct 25. Review.

PMID:
27561079
7.

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.

Lo Nigro C, Ricci V, Vivenza D, Granetto C, Fabozzi T, Miraglio E, Merlano MC.

World J Gastroenterol. 2016 Aug 14;22(30):6944-54. doi: 10.3748/wjg.v22.i30.6944. Review.

8.

Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.

Locke M, Ghazaly E, Freitas MO, Mitsinga M, Lattanzio L, Lo Nigro C, Nagano A, Wang J, Chelala C, Szlosarek P, Martin SA.

Cell Rep. 2016 Aug 9;16(6):1604-1613. doi: 10.1016/j.celrep.2016.06.097. Epub 2016 Jul 21.

9.

Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma.

Benhamou Y, Picco V, Raybaud H, Sudaka A, Chamorey E, Brolih S, Monteverde M, Merlano M, Lo Nigro C, Ambrosetti D, Pagès G.

Oncotarget. 2016 Jul 12;7(28):44236-44251. doi: 10.18632/oncotarget.10005.

10.

Reoxygenation Reverses Hypoxia-related Radioresistance in Head and Neck Cancer Cell Lines.

Tonissi F, Lattanzio L, Astesana V, Cavicchioli F, Ghiglia A, Monteverde M, Vivenza D, Gianello L, Russi E, Merlano M, Lo Nigro C.

Anticancer Res. 2016 May;36(5):2211-5.

PMID:
27127125
11.

E1 detection as prognosticator in human papillomavirus-positive head and neck cancers.

Vivenza D, Lo Nigro C, Denaro N, Fortunato M, Monteverde M, Tonissi F, Lattanzio L, Astesana V, Gloghini A, Volpi CC, Russi E, Merlano MC.

Int J Biol Markers. 2016 Apr-Jun;31(2):0. doi: 10.5301/jbm.5000193. Epub 2016 Mar 22.

PMID:
27040135
12.

Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.

Griseri P, Garrone O, Lo Sardo A, Monteverde M, Rusmini M, Tonissi F, Merlano M, Bruzzi P, Lo Nigro C, Ceccherini I.

Oncotarget. 2016 May 3;7(18):26465-79. doi: 10.18632/oncotarget.8417.

13.

Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.

Lattanzio L, Milano G, Monteverde M, Tonissi F, Vivenza D, Merlano M, Lo Nigro C.

Anticancer Drugs. 2016 Jul;27(6):533-9. doi: 10.1097/CAD.0000000000000360.

PMID:
26982238
14.

Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up.

Vivenza D, Monteverde M, Lattanzio L, Tonissi F, Astesana V, Denaro N, Comino A, Russi E, Lo Nigro C, Merlano M.

Int J Biol Markers. 2016 May 28;31(2):e183-92. doi: 10.5301/jbm.5000192.

PMID:
26916894
15.

Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients.

Lo Nigro C, Ricci V, Vivenza D, Monteverde M, Strola G, Lucio F, Tonissi F, Miraglio E, Granetto C, Fortunato M, Merlano MC.

World J Gastrointest Oncol. 2016 Feb 15;8(2):222-30. doi: 10.4251/wjgo.v8.i2.222.

16.

p16 cutoff in head and neck squamous cell carcinoma: correlation between tumor and patient characteristics and outcome.

Merlano MC, Denaro N, Vivenza D, Monteverde M, Russi E, Lerda W, Comino A, Lo Nigro C.

Int J Biol Markers. 2016 Feb 28;31(1):e44-52. doi: 10.5301/jbm.5000175.

PMID:
26481441
17.

Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer.

O'Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K, Lackner M, Wischnewsky MB, Crook T, Lo Nigro C, Schmid P.

Br J Cancer. 2015 Sep 15;113(6):970-8. doi: 10.1038/bjc.2015.302. Epub 2015 Sep 1.

18.

Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).

Cabrini G, Fabbri E, Lo Nigro C, Dechecchi MC, Gambari R.

Int J Oncol. 2015 Aug;47(2):417-28. doi: 10.3892/ijo.2015.3026. Epub 2015 May 29. Review.

19.

The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.

Tonissi F, Lattanzio L, Merlano MC, Infante L, Lo Nigro C, Garrone O.

Invest New Drugs. 2015 Aug;33(4):801-9. doi: 10.1007/s10637-015-0249-z. Epub 2015 May 7.

PMID:
25947567
20.

The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients.

Monteverde M, Milano G, Strola G, Maffi M, Lattanzio L, Vivenza D, Tonissi F, Merlano M, Lo Nigro C.

Crit Rev Oncol Hematol. 2015 Aug;95(2):179-90. doi: 10.1016/j.critrevonc.2015.02.014. Epub 2015 Mar 12. Review.

PMID:
25819749
21.

Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines.

Lattanzio L, Tonissi F, Monteverde M, Vivenza D, Russi E, Milano G, Merlano M, Lo Nigro C.

Invest New Drugs. 2015 Apr;33(2):310-20. doi: 10.1007/s10637-015-0210-1. Epub 2015 Jan 22.

PMID:
25603975
22.

Fully covered self-expandable metal stent in tracheobronchial disorders: clinical experience.

Marchese R, Poidomani G, Paglino G, Crimi C, Lo Nigro C, Argano V.

Respiration. 2015;89(1):49-56. doi: 10.1159/000368614. Epub 2015 Jan 15.

23.

MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens.

Lattanzio L, Borgognone M, Mocellini C, Giordano F, Favata E, Fasano G, Vivenza D, Monteverde M, Tonissi F, Ghiglia A, Fillini C, Bernucci C, Merlano M, Lo Nigro C.

Int J Biol Markers. 2015 May 26;30(2):e208-16. doi: 10.5301/jbm.5000126.

PMID:
25588856
24.

Non coding RNAs in head and neck squamous cell carcinoma (HNSCC): a clinical perspective.

Denaro N, Merlano MC, Russi EG, Lo Nigro C.

Anticancer Res. 2014 Dec;34(12):6887-96. Review.

PMID:
25503114
25.

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer.

Rudraraju B, Droog M, Abdel-Fatah TM, Zwart W, Giannoudis A, Malki MI, Moore D, Patel H, Shaw J, Ellis IO, Chan S, Brooke GN, Nevedomskaya E, Lo Nigro C, Carroll J, Coombes RC, Bevan C, Ali S, Palmieri C.

Breast Cancer Res Treat. 2014 Sep;147(2):295-309. doi: 10.1007/s10549-014-3098-0. Epub 2014 Aug 22.

PMID:
25141981
26.

A blood test to identify when melanoma metastasizes: a reality for melanoma management?

Hatzimichael E, Syed N, Lo Nigro C, Crook T.

Melanoma Manag. 2014 Aug;1(1):11-14. doi: 10.2217/mmt.14.11. Epub 2014 Sep 5. No abstract available.

27.

How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis.

Hatzimichael E, Syed N, Lo Nigro C, Rao B, Crook T.

Expert Rev Mol Diagn. 2014 Jul;14(6):639-42. doi: 10.1586/14737159.2014.928204. Epub 2014 Jun 13.

PMID:
24926921
28.

Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.

Allen MD, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M, Syed N, Lo Nigro C, Lattanzio L, Chmielewska-Kassassir M, Tomlinson I, Roylance R, Whitaker HC, Warren AY, Neal D, Frezza C, Beltran L, Jones LJ, Chelala C, Wu BW, Bomalaski JS, Jackson RC, Lu YJ, Crook T, Lemoine NR, Mather S, Foster J, Sosabowski J, Avril N, Li CF, Szlosarek PW.

Cancer Res. 2014 Feb 1;74(3):896-907. doi: 10.1158/0008-5472.CAN-13-1702. Epub 2013 Nov 27.

29.

A PNA-mediated clamping PCR for routine detection of KRAS mutations in colorectal carcinoma.

Messa F, Tonissi F, Millo E, Bracco E, Ungari S, Lattanzio L, Merlano M, Damonte G, Lo Nigro C.

Int J Biol Markers. 2014 Mar 24;29(1):e55-61. doi: 10.5301/jbm.5000052.

PMID:
24242294
30.

Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma.

Vivenza D, Feola M, Garrone O, Monteverde M, Merlano M, Lo Nigro C.

Int J Biol Markers. 2013 Dec 17;28(4):e336-47. doi: 10.5301/jbm.5000041.

PMID:
23999848
31.

Postoperative laryngeal symptoms in a general surgery setting. Clinical study.

Geraci G, Cupido F, Lo Nigro C, Sciuto A, Sciumè C, Modica G.

Ann Ital Chir. 2013 Jul-Aug;84(4):377-83.

PMID:
23918003
32.

Role of IL-8 induced angiogenesis in uveal melanoma.

Lattanzio L, Tonissi F, Torta I, Gianello L, Russi E, Milano G, Merlano M, Lo Nigro C.

Invest New Drugs. 2013 Oct;31(5):1107-14. doi: 10.1007/s10637-013-0005-1. Epub 2013 Aug 4.

PMID:
23912257
33.

Asymptomatic bone cement pulmonary embolism after vertebroplasty: case report and literature review.

Geraci G, Lo Iacono G, Lo Nigro C, Cannizzaro F, Cajozzo M, Modica G.

Case Rep Surg. 2013;2013:591432. doi: 10.1155/2013/591432. Epub 2013 May 7.

34.

Carcinoma showing thymus-like differentiation (CASTLE): a case report.

Geraci G, Lo Nigro C, Sciuto A, Modica R, Francesco C, Sciumè C, Attard A, Modica G.

Ann Ital Chir. 2013 Jan-Feb;84(1):77-80.

PMID:
23445782
35.

Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma.

Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, Evans A, Thompson A, Leigh I, Fleming C, Inman GJ, Proby C, Crook T.

J Invest Dermatol. 2013 May;133(5):1278-85. doi: 10.1038/jid.2012.493. Epub 2013 Feb 14.

36.

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.

Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E, Bomalaski J, Szlosarek P, Awad M, O'Neil K, Roncaroli F, Crook T.

Cell Death Dis. 2013 Jan 17;4:e458. doi: 10.1038/cddis.2012.197.

37.

Surgical treatment of thymoma: personal experience.

Lo Nigro C, Geraci G, Sciuto A, Li Volsi F, Cupido F, Modica G.

G Chir. 2012 Oct;33(10):318-23.

PMID:
23095559
38.

Bile leaks after videolaparoscopic cholecystectomy: duct of Luschka. Endoscopic treatment in a single centre and brief literature review on current management.

Lo Nigro C, Geraci G, Sciuto A, Li Volsi F, Sciume C, Modica G.

Ann Ital Chir. 2012 Jul-Aug;83(4):303-12. Review.

PMID:
23012722
39.

Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells.

Lattanzio L, Tonissi F, Monteverde M, Milano G, Merlano MC, Lo Nigro C.

Anticancer Drugs. 2013 Feb;24(2):120-30. doi: 10.1097/CAD.0b013e328358d1dc.

PMID:
22990129
40.

Bilateral lung and liver hydatid cysts. Case report.

Geraci G, Sciuto A, Lo Nigro C, Sciumè C, Li Volsi F, Cupido F, Calbo E, Modica G.

G Chir. 2012 Jun-Jul;33(6-7):229-33.

PMID:
22958805
41.

The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma.

Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D, Monteverde M, Merlano M, Papoudou-Bai A, Bai M, Schmid P, Stebbing J, Bower M, Dyer MJ, Karran LE, ElguetaKarstegl C, Farrell PJ, Thompson A, Briasoulis E, Crook T.

Br J Cancer. 2012 Oct 9;107(8):1423-32. doi: 10.1038/bjc.2012.380. Epub 2012 Sep 6.

42.

Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse.

Palmieri C, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Fortunato M, Syed N, Thompson A, Garrone O, Merlano M, Lo Nigro C, Crook T.

Br J Cancer. 2012 Aug 7;107(4):732-8. doi: 10.1038/bjc.2012.308. Epub 2012 Jul 10.

43.

Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.

Sudaka A, Susini A, Lo Nigro C, Fischel JL, Toussan N, Formento P, Tonissi F, Lattanzio L, Russi E, Etienne-Grimaldi MC, Merlano M, Milano G.

Invest New Drugs. 2013 Feb;31(1):59-65. doi: 10.1007/s10637-012-9834-6. Epub 2012 Jun 20.

PMID:
22714791
44.

Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer.

Merlano MC, Monteverde M, Colantonio I, Denaro N, Lo Nigro C, Natoli G, Giurlanda F, Numico G, Russi E.

Oral Oncol. 2012 Oct;48(10):1051-1057. doi: 10.1016/j.oraloncology.2012.05.001. Epub 2012 Jun 2.

PMID:
22658677
45.

NT5E CpG island methylation is a favourable breast cancer biomarker.

Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T.

Br J Cancer. 2012 Jun 26;107(1):75-83. doi: 10.1038/bjc.2012.212. Epub 2012 May 31.

46.

Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas.

Palmieri C, Rudraraju B, Monteverde M, Lattanzio L, Gojis O, Brizio R, Garrone O, Merlano M, Syed N, Lo Nigro C, Crook T.

Br J Cancer. 2012 Jul 10;107(2):375-81. doi: 10.1038/bjc.2012.231. Epub 2012 May 29.

47.

Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.

Guérin O, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, Formento P, Lattanzio L, Maffi M, Tonissi F, Ortholan C, Pagès G, Fischel JL, Lo Nigro C, Merlano M, Milano G.

Urol Oncol. 2013 Nov;31(8):1567-75. doi: 10.1016/j.urolonc.2012.03.003. Epub 2012 May 17.

PMID:
22608542
48.

MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.

Vivenza D, Gasco M, Monteverde M, Lattanzio L, Syed N, Colantonio I, Denaro N, Natoli G, Comino A, Russi E, Merlano M, Crook T, Lo Nigro C.

Oral Oncol. 2012 Jul;48(7):602-7. doi: 10.1016/j.oraloncology.2012.01.022. Epub 2012 Feb 21.

PMID:
22356895
49.

Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications.

Hatzimichael E, Dasoula A, Kounnis V, Benetatos L, Lo Nigro C, Lattanzio L, Papoudou-Bai A, Dranitsaris G, Briasoulis E, Crook T.

Leuk Lymphoma. 2012 Sep;53(9):1709-13. doi: 10.3109/10428194.2012.661854. Epub 2012 Mar 13.

PMID:
22288719
50.

Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis.

Garrone O, Crosetto N, Lo Nigro C, Catzeddu T, Vivenza D, Monteverde M, Merlano M, Feola M.

Cardiovasc Toxicol. 2012 Jun;12(2):135-42. doi: 10.1007/s12012-011-9149-4.

PMID:
22189487

Supplemental Content

Loading ...
Support Center